ClinicalTrials.gg
CompletedNCT03403374RAMANUpdated May 29, 2024Results posted

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

A Phase 4 interventional study of evolocumab in Homozygous Familial Hypercholesterolemia HoFH, sponsored by Amgen. Completed at 12 sites in India. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
33rd of 36
30 · median 308
Started
2018
with 1 other
Phase 4
7 of 36
1 open now
Registered
29th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 33rd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 4, and was the 29th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

To describe the safety and tolerability of evolocumab in participants with homozygous familial hypercholesterolemia (HoFH) in India. All participants will receive evolocumab over an 8-week period.

Read the detailed description

An open-label, multicentre, phase 4 study to describe the safety and tolerability of evolocumab in 30 Indian participants with HoFH. Subjects who meet the inclusion/exclusion criteria and laboratory assessments at screening will be enrolled and will be required to maintain their current lipid-lowering drug therapy throughout the duration of the trial. Participants will receive evolocumab 420 mg subcutaneous (SC) once monthly (QM) and study visits will occur approximately every 4 weeks. Apheresis participants will receive evolocumab 420 mg SC every 2 weeks to correspond with their apheresis schedule. Final administration of evolocumab (for all participants) will occur at week 8. The end of study (EOS) visit will occur at week 12 for all participants.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia HoFH

Keywords

  • Evolocumab
  • Hypercholesterolemia
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 12 to ≤ 80 years of age at the time of signing the
  • Diagnosis of HoFH based on low-density lipoprotein cholesterol (LDL-C), familial history and xanthoma
  • On a low-fat diet and receiving background lipid-lowering therapy stable for 4 weeks prior to screening and during the time frame of the trial
  • Fasting LDL-C at screening > 130 mg/dL (3.4 mmol/L)
  • Fasting triglycerides at screening ≤ 400 mg/dL (4.5 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Use of mipomersen or lomitapide within 6 months of screening.
  • Known active infection or major hematologic, renal, metabolic, gastrointestinal, hepatic, or endocrine dysfunction
  • Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies)
  • Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed
  • Female subjects of unwilling to use an acceptable method of effective
  • Subject has known sensitivity to any of the products to be administered during dosing
  • History or evidence of any other disorder, condition or disease
  • Subject has previously received evolocumab or any other proprotein convertase subtilisin/kexin type 9 (PKSK-9)-inhibiting therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).

    Drug: evolocumab

Interventions

  • Administered by SC injection via autoinjector (AI)/pen

    Also known as: Repatha®, EvoMab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Includes both serious and non-serious adverse events (AEs). AE: any untoward medical occurrence in a participant. SAE: an AE that meets 1 on the following serious criteria: fatal; life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. TEAE: any AE starting on or after the first dose of study drug and up to and including 30 days after the end of study drug or the end of study date, whichever is earlier.

    Time frame: 12 weeks

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame: baseline, week 12

  2. Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)

    Time frame: baseline, week 12

  3. Percent Change From Baseline to Week 12 in Lipoprotein(a) (Lp[a])

    Time frame: baseline, week 12

07

Results

Posted Nov 3, 2020

Participant flow

Participants were enrolled at 10 study centers in India. The first participant was enrolled on 04 August 2018 and the last participant was enrolled on 29 August 2019.

Participant flow — Overall Study
MilestoneEvolocumab
Started30
Completed29
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Includes both serious and non-serious adverse events (AEs). AE: any untoward medical occurrence in a participant. SAE: an AE that meets 1 on the following serious criteria: fatal; life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. TEAE: any AE starting on or after the first dose of study drug and up to and including 30 days after the end of study drug or the end of study date, whichever is earlier.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsEvolocumab
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)10
SecondaryPercent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)
Time frame:
baseline, week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)
percent changeEvolocumab
Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)-6.4 ± 22.7
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)
Time frame:
baseline, week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)
percent changeEvolocumab
Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)-6.0 ± 19.8
SecondaryPercent Change From Baseline to Week 12 in Lipoprotein(a) (Lp[a])
Time frame:
baseline, week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 in Lipoprotein(a) (Lp[a])
percent changeEvolocumab
Percent Change From Baseline to Week 12 in Lipoprotein(a) (Lp[a])-0.2 ± 26.2

Adverse events

Collected over All-cause mortality: from enrollment (up to 4 weeks prior to treatment) through end of study (week 12). Serious and other adverse events: from the first dose of study treatment through end of treatment (at week 8) plus 4 weeks (week 12).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab0/30 (0%)2/30 (6.7%)8/30 (26.7%)
Most frequent serious events
Most frequent serious events
EventEvolocumab
Coronary artery diseaseCardiac disorders1/30
SyncopeNervous system disorders1/30
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEvolocumab
Angina pectorisCardiac disorders1/30
Injection site painGeneral disorders1/30
Injection site swellingGeneral disorders1/30
Peripheral swellingGeneral disorders1/30
PyodermaInfections and infestations1/30
VaricellaInfections and infestations1/30
ArthralgiaMusculoskeletal and connective tissue disorders1/30
ArthritisMusculoskeletal and connective tissue disorders1/30
CoughRespiratory, thoracic and mediastinal disorders1/30
Diabetic woundSkin and subcutaneous tissue disorders1/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Evolocumab
Mean23.2 ± 13.1
Age, Customized
Age, Customized(Participants)Evolocumab
Adolescents (12 - 17 years old)13
Adults (18 - 64 years old)16
Adults (65 - 84 years old)1
Sex: Female, Male
Sex: Female, Male(Participants)Evolocumab
Female13
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Evolocumab
Hispanic or Latino0
Not Hispanic or Latino30
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Evolocumab
Asian30
Low-Density Lipoprotein Cholesterol (LDL-C)
Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL)Evolocumab
Mean473.5 ± 135.2
Apolipoprotein B (ApoB)
Apolipoprotein B (ApoB)(mg/dL)Evolocumab
Mean275.3 ± 69.1
Lipoprotein(a) (Lp[a])
Lipoprotein(a) (Lp[a])(nmol/L)Evolocumab
Mean201.3 ± 177.6
08

Study locations

12 sites
  • Research Site
    New Delhi, Delhi 110 002, India
  • Research Site
    New Delhi, Delhi 110 029, India
  • Research Site
    New Delhi, Delhi 110 060, India
  • Research Site
    New Delhi, Delhi 110 062, India
  • Research Site
    Ahmedabad, Gujarat 380 054, India
  • Research Site
    Bangalore, Karnataka 560 017, India
  • Research Site
    Belagavi, Karnataka 590010, India
  • Research Site
    Kochi, Kerala 682 027, India
  • Research Site
    Mumbai, Maharashtra 400 007, India
  • Research Site
    Pune, Maharashtra 411 005, India
  • Research Site
    Pune, Maharashtra 411 006, India
  • Research Site
    Lucknow, Uttar Pradesh 226 003, India
09

References and documents

Publications

  • Raal FJ, Hegele RA, Ruzza A, Lopez JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May;44(5):1156-1164. doi: 10.1161/ATVBAHA.123.320268. Epub 2024 Mar 28. PubMed 38545781 ↗
  • Bansal S, Ruzza A, Sawhney J, Kulkarni G, Iyengar S, Mehta V, Hamer A, Wu Y, Raal FJ. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec;15(6):814-821. doi: 10.1016/j.jacl.2021.10.003. Epub 2021 Oct 20. PubMed 34750081 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Nov 2019, 15 months.

Results were first posted in Nov 2020, 11 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Jan 18, 2018
StartActual
Aug 4, 2018
Primary completionActual
Nov 27, 2019
CompletionActual
Nov 27, 2019
Results first posted
Nov 3, 2020
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03403374
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Aug 4, 2018
Primary completion
Nov 27, 2019
Completion
Nov 27, 2019
Results posted
Nov 3, 2020
Last update
May 29, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion